google-site-verification: googlec8651b231a5582bd.html
top of page
tim78593

Knee-deep in meniscus redesign: the story of Atlanta’s OrthoPreserve

There are 1.4 million meniscus procedures performed in the US and Europe every single year. Most of those are meniscetomy which is when the meniscus is removed. The problem is that once it is gone, so is the cushioning that protects the knee joint and cartilage, accelerating arthritis. A quarter of people continue to have pain after a few years. Millions of people have this procedure and it’s not the best answer.





Today’s guest is Jonathan Schwartz, CEO of OrthoPreserve, a company designing an artificial meniscus implant designed to mitigate the arthritis that often results a few years after traditional knee surgery. We discussed:

  • The problem with having your meniscus removed

  • Why he started the company

  • What the process of transitioning from academic to entrepreneurship was like for him

  • How having space at Biospark influenced the early days of the startup

  • How he did it all while having a day job

  • How big the meniscus procedure market is

  • How he met the Orthopaedic surgeons on his advisory board


But that’s not all – have a listen to hear more!


About Jonathan Schwartz

Jonathan invented the company's revolutionary meniscus implant in 2016 while pursuing his graduate studies in biomechanical engineering at Georgia Institute of Technology. Jonathan’s career began in the polymer science industry, where he focused on research. He then transitioned into biotech engineering project management, gaining broad expertise across R&D, manufacturing, regulatory compliance, and operations. He connected with the orthopedic clinician co-founders in 2021 to start OrthoPreserve in an attempt to bring the meniscus implant to market to serve patients in need. His diverse background drives OrthoPreserve’s innovation in developing minimally invasive solutions for orthopedic care.


Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

20 views0 comments

Comentarios


bottom of page